



ALRT⁺

Smarter Diabetes
Management

OTCMKTS : ALRT

Investor Presentation

OCTOBER 2021

Meet ALRT

Transforming Diabetes Care



Mission

To assist patients and healthcare professionals in improving diabetes outcomes and quality of care, as well as reducing complications and containing costs.

What We Do

To process accurate and reliable data for ease of use in managing diabetes by healthcare professionals to improve patient outcomes.

Divisions

Two divisions present; Human Health and Animal Health. Both divisions focused on cutting-edge diabetes innovation.

Milestones

Development

Pilot & Clinical Trials in the US, Canada, and Singapore

FDA Cleared Insulin Dose Adjustment

Patent Pending Predictive A1C Feature

FDA Cleared BGM Platform

Future

2022 Launch of Centre for Diabetes Excellence in Canada

2023 ALRT Brand Human CGM

Current

Diabetes Singapore Partnership

Animal CGM

Marketing in US, Canada, Singapore & Latin America

Current & Future Product Offerings

ALRT BGM Platform (Current)

GluCurve™ Pet CGM (Future)

Blue-Sky Opportunity for Data Monetization

CGM

Continuous Glucose Monitor

What is a CGM?

- Small wearable device that checks glucose levels (blood sugar) in diabetics
- Continuous recording as opposed to a Blood Glucose Monitor (BGM)

CGM Sensor


- Adhesive pad with small needle that penetrates skin
- Contains enzymes on the needle that detect glucose within interstitial fluid
- Glucose data is sent to a transmitter, which is attached to the sensor
- Transmitter data is wirelessly sent to a monitor via Bluetooth
- Each sensor lasts approximately 10 to 14 days



ALRT⁺

Picture source: [VibrantDoc](#)


Our Process



Mass data collection via low-cost blood glucose meters & CGM



Our powerful AI, Predictive A1C[®], combs through millions of data points to suggest treatment plans



Findings are delivered via our patient management portal directly to the healthcare provider

An Opportunity for Pets

Current Situation

- Blood Glucose Meters (BGM) are used as the current method of measuring glucose levels in pets
- Human CGM is used as an off-label alternative

Labor Intensive

- Blood is drawn every 2 hours for 10-12 hours
- Takes 2+ staff members


Inefficient & Inaccurate

- Staff must record and plot data manually
- Pets experience high levels of stress during this process, affecting results

High Cost

- Average cost is \$150, owners pay up to \$300+
- Unprofitable for veterinarians

Unbalanced Glucose Curve (Dog Sample)¹



An unbalanced glucose curve is the result of many factors in pets, including stress (normal levels range from 60 – 110 mg/dL)²

¹ Adapted from K9diabetes, <http://www.k9diabetes.com/insulinfood.html>

² According to the National Center for Biotechnology Information (NCBI)



The GluCurve™ Pet CGM

- The world's first and only pet CGM for use by veterinarians
- Applied in minutes – minimizes trauma and pet is sent home quickly
- Readings recorded in a home environment – stress free results (no elevated glucose levels)
- Automatic readings every 5 minutes, 288 per day, for up to 14 days
- Profitable for veterinarians and more affordable for pet owners (vs. BGM, Human CGM)
- Data is customized for veterinarians' interpretation via Patient Management Software – insulin dose calculations & suggestions, daily glucose curves and best care guidelines
- Allows for remote care of pets

Market Overview

Part 1 | A promising landscape in animal health

Diabetic Cat & Dog Population as of 2018


- United States: 1M
- Global: 4.5M
- **Premium market** for racehorses, zoos, reserves/shelters, etc.

Morgan Stanley Research¹

- US Pet Industry has reached inflection point
- 8% CAGR today vs. 3% from last decade
- **“US \$100B** pet industry is poised to nearly **tripled to US \$275B** by 2030”
- Positive Factors include surge in new owners, favorable demographics, increased pet-per spending

¹ As of April 7th, 2021, <https://www.morganstanley.com/ideas/us-pets-investing-trend>

² US ownership: APPA 2017-2018 National Pet Owners Survey, <https://www.iii.org/fact-statistic/facts-statistics-pet-statistics>
Global Ownership, <https://www.statista.com/statistics/1044386/dog-and-cat-pet-population-worldwide/>



Part 1

Acceptability

- 97% of veterinarians surveyed would use GluCurve™ Pet CGM
- Pet owners would prefer the GluCurve™ Pet CGM over current methods was ranked by 75% of veterinarians as a top reason for using ALRT


Profitability

- 83% of veterinarian felt the surveyed cost was “reasonable” or “too low”
- Average expected charge to pet owners was \$150

Use rate expected to grow due to low cost, ease of use, and accuracy¹

¹ Conducted by SmartPharma, April 2021

How Often Doctors of Veterinary Medicine (DVMs) See Pets for Diabetes Mellitus (DM)



Upcoming Strategic Partnerships



Partnership Discussions¹

- ALR Technologies is in advanced discussions with two key global pharmaceutical companies in animal health
- Partner to take over sales and marketing efforts
- Instant access to global community of veterinarian clinics utilizing a long history of well-established relationships with veterinarian clinics worldwide
- Partnership will give confidence to veterinarians

¹ ALRT [Press Release](#)

Co-Marketing


U.S. Distribution

Global Distribution

New Sales Channels

Timelines & Objectives

From 2021 to 2023




Blue Sky Opportunity

Big Data

Data Collection & Monetization

- Our data collection system gathers a data point every 5 minutes, for 288 data points every 24 hours
- Over 4000 data points recorded during the 14-day lifespan of each CGM
- At scale, our system will be collecting trillions of data points across all of our patient populations
- Opens up potential studies, partnerships and joint ventures to monetize this data
- Our in-house artificial intelligence software, Predictive A1C will continuously deliver actionable insights to healthcare providers through our proprietary Patient Management Portal





Sidney S. Chan
Chairman & CEO

Mr. Chan has been involved in managing and developing ALR Technologies since August 1997 and was instrumental in taking the company public. Prior to ALRT, Mr. Chan had an extensive background in structured finance as President and CEO of the Knight's Group of Companies. Prior to the founding of the Knight's Group of Companies Mr. Chan worked for the predecessor companies of RBC Dominion Securities as well as Cominco, the mining subsidiary of Canadian Pacific.



**Dr. Kent Stoneking,
Pharm.D., CDE**
Director, Clinical Program
Development

Dr. Stoneking is a pharmacist and Certified Diabetes Educator (CDE) who has extensive, hands-on experience working with a network of primary care and endocrinology providers to assist patients with medications, diabetes education and self-management training. He has practiced in community, academic, and corporate pharmacy settings. He currently serves as Director of Pharmacy and Wellness at Pinnacle Medical Solutions, LLC.



Joe Stern
Head of Animal Health

Mr. Stern heads up the Animal Health Division of ALR Technologies. Mr. Stern possesses over 20 years of experience in various industries, specializing in project management and operations, with 15 years spent at a Fortune 50 company. Mr. Stern has led several large scale B2B projects worth hundreds of millions of dollars and helped lead his region's revenue from its infancy to over half a billion dollars annually. His focus was to oversee projects in construction, government contracts, business partnerships, product launches, product development, information systems design and deployment (billing, platforms, apps), fleet purchasing and maintenance, as well as training of 1,000+ employees on various technologies.



Pete Riojas
Head of Global Commercial and
Business Development

Mr. Riojas heads up Global Business Development, sales, and marketing activities for ALR Technologies. Mr. Riojas has over 30 years in the Pharmaceutical Industry, where he held Executive and Senior Level positions with large, mid-size, and small biotech pharmaceutical companies in sales/management, marketing, training, operations, and strategic business planning. He managed products that totaled 2 billion in sales. In addition, he coordinated and implemented processes strategic planning to exceed sales goals. With 25+ years specializing in Diabetes therapies, including 3 years dedicated to Animal Health, Mr. Riojas has successfully built out multiple sales teams for launch excellence, yielding 37 products over his career.



**Steven Brassard,
CPA, CA, C.Dir, MPAcc**
Director, Finance, Accounting and
Administration

Mr. Brassard heads up ALR Technologies' company finance and administration. Mr. Brassard, is a professional accountant with 15 years of governance, management, finance and accounting experience. He has held management positions with both public and private companies in the technology, agriculture, manufacturing and hospitality industries; as well as providing consulting services to a variety of businesses. Besides his professional career in finance and consulting, Mr. Brassard also has extensive experience in project commercialization for tech start-ups and intellectual properties through government funding. Mr. Brassard is a Chartered Professional Accountant, a Chartered Director and holds a Master Professional Accountant designation from the University of Saskatchewan.

This presentation contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties, and assumptions. When used, the words "estimate", "expect", "anticipate", "believe", "will" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance, or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the Company's quarterly filings with the Securities Exchange Commission.

Thank you!

Have any questions?

For more information or investment
opportunities please contact
ir@alrt.com

ALRT 

OTCMKTS : ALRT

Investor Presentation

OCTOBER 2021